Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer
| Autor: | Louis Tassy, Joëlle Micallef, Maria Paciencia, Maud Cecile, Annie-Pierre Jonville-Béra, Ségolène Duran, Frédérique Rousseau, Franck Rouby, Emanuel Nicolas, Anne Madroszyk, Renaud Sabatier, Cecile Braticevic |
|---|---|
| Přispěvatelé: | Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS) |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty Lung Neoplasms [SDV]Life Sciences [q-bio] Routine practice B7-H1 Antigen 03 medical and health sciences 0302 clinical medicine Antineoplastic Agents Immunological Older patients Internal medicine Carcinoma Non-Small-Cell Lung Pharmacovigilance medicine Humans 030212 general & internal medicine Adverse effect Lung cancer Aged Retrospective Studies Aged 80 and over business.industry medicine.disease 3. Good health Nivolumab Oncology 030220 oncology & carcinogenesis Cohort Female Non small cell Geriatrics and Gerontology business |
| Zdroj: | Journal of Geriatric Oncology Journal of Geriatric Oncology, 2018, 9 (5), pp.494-500. ⟨10.1016/j.jgo.2018.02.011⟩ Journal of Geriatric Oncology, Elsevier, 2018, 9 (5), pp.494-500. ⟨10.1016/j.jgo.2018.02.011⟩ |
| ISSN: | 1879-4068 1879-4076 |
| Popis: | Background: Nivolumab is approved worldwide as second-line treatment for metastatic non-small cell lung cancer (NSCLC). Despite the fact that most of these cancers are being diagnosed in the older patients, few of the patients were included in pivotal trials. We aimed to describe efficacy and safety in a ``real-world'' older population. Patients and Methods: We retrospectively collected data from older patients (>= 70 years old) with advanced or metastatic NSCLC treated with Nivolumab in our institution. We analyzed safety (CTCAE v4.0 criteria), efficacy (clinical benefit rate, progression-free survival, and overall survival), and correlated these features to geriatric parameters and PD-L1 expression. Along with this cohort, we assessed safety at a national level by retrieving all cases of Nivolumab (prescribed for NSCLC) induced adverse events analyzed by the French pharmacovigilance network during the inclusion period. Results: From July 2015 to September 2016, 30 patients were enrolled with a median age of 752. Clinical benefit rate was 30.6%. Median progression-free survival and overall survival were 33 and 7.1 months, respectively. Fifteen patients (50%) presented an immune-related adverse event (IrAE) of any grade, including four high grade IrAEs. Two hundred and eighty IrAEs had been notified to the French pharmacovigilance network including 91 (35.2%) concerning older patients. Frequency and pattern of IrAEs were similar for older patients and younger subjects. Conclusions: Even though frequency and patterns of IrAEs are different from pivotal studies, these results don't seem specific to older patients. Further prospective investigations are needed to better characterize and predict the impact of Nivolumab on older patients with NSCLC. (C) 2018 Elsevier Ltd. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect